Mixed colloids and acute kidney injury: a case of selection bias?

A. Groeneveld,R. Navickis,M. Wilkes

DOI: https://doi.org/10.1186/s13054-015-0797-9

IF: 15.1

2015-04-30

Critical Care

Abstract:

What problem does this paper attempt to address?

An In Silico Investigation of a Lobe-Specific Targeted Pulmonary Drug Delivery Method

Yu Feng,Xiaole Chen,Mingshi Yang

DOI: https://doi.org/10.1115/dmd2018-6928

2018-04-09

Abstract:Nowadays, “personalized medicine” is starting to replace the current “one size fits all” approach. The goal is to have the right drug with the right dose for the right patient at the right time and location. Indeed, conventional pulmonary drug delivery devices still have poor efficiencies (<25%) for delivering drugs to the lung tumor sites. Major portions of the aggressive medicine deposit on healthy tissue, which causes severe side effects and induces extra health care expenses. Therefore, a new targeted pulmonary drug delivery method is proposed and evaluated using the Computational Fluid-Particle Dynamics (CFPD) method to achieve the lobe-specific delivery. By controlling the release position and velocity of the drug particles at the mouth inlet, drug deposition efficiency (DE) in a designated lobe can be increased up to 90%. Intersubject variability has also been investigated using the noninvasive in silico tool. Results indicate that the glottis constriction ratio is a key factor to influence the effectiveness of the purposed targeted drug delivery method. Although lobe-specific pulmonary drug delivery can be realized, the actuation flow rate must be lower than 2 L/min, and the glottis constriction ratio has a significant impact on the effectiveness of the targeting method. Also, a design idea using e-cigarette as the prototype is proposed as the next-generation inhaler to accommodate the operational flexibility restrictions.
Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System

Tomasz R. Sosnowski

DOI: https://doi.org/10.3390/pharmaceutics16010097

IF: 6.525

2024-01-11

Pharmaceutics

Abstract:Pharmaceutical aerosols play a key role in the treatment of lung disorders, but also systemic diseases, due to their ability to target specific areas of the respiratory system (RS). This article focuses on identifying and clarifying the influence of various factors involved in the generation of aerosol micro- and nanoparticles on their regional distribution and deposition in the RS. Attention is given to the importance of process parameters during the aerosolization of liquids or powders and the role of aerosol flow dynamics in the RS. The interaction of deposited particles with the fluid environment of the lung is also pointed out as an important step in the mass transfer of the drug to the RS surface. The analysis presented highlights the technical aspects of preparing the precursors to ensure that the properties of the aerosol are suitable for a given therapeutic target. Through an analysis of existing technical limitations, selected strategies aimed at enhancing the effectiveness of targeted aerosol delivery to the RS have been identified and presented. These strategies also include the use of smart inhaling devices and systems with built-in AI algorithms.

pharmacology & pharmacy
Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale® system: A first evaluation in humans

Per Gerde,Carl-Olof Sjöberg,Helen Bäckroos,Joakim Englund,Marit Wangheim,Helena Litorp

DOI: https://doi.org/10.1016/j.ejps.2024.106742

IF: 5.112

2024-05-01

European Journal of Pharmaceutical Sciences

Abstract:BACKGROUND: In development of inhaled drugs- and formulations the measured concentration in the systemic circulation is often used as a surrogate for local dosimetry in the lungs. To further elucidate regional differences in the fate of drugs in the lungs, different aerodynamic sizes of aerosols have been used to target major airway regions. An alternative approach to achieve regional targeting of aerosols, is to use a defined aerosol bolus together with a bolus breath hold strategy. A small volume of test aerosol is intercalated and stopped at different penetration depths, to achieve increased drug deposition at chosen lung locations. Drug permeation from the lung regions is then investigated by repeatedly sampling venous blood from the systemic circulation. The PreciseInhale® (PI) exposure platform was developed to allow generation of aerosols from different sources, including clinical inhalers, into a holding chamber, for subsequent use with alternative exposure modules in vitro and in vivo. In the current first-in-human study was investigated the feasibility of a new clinical exposure module added to the PI system. By extracting aerosol puffs from a medical inhaler for subsequent delivery to volunteers, it was possible to administer whole lung exposures, as well as regional targeting exposures.METHODS: Aerosols containing 250 µg/25 µg fluticasone propionate (FP)/salmeterol xinafoate (SMX) were automatically actuated and extracted from the pressurized Metered Dose Inhaler (pMDI) Evohaler Seretide forte into the PI system's holding chamber, then administered to the healthy volunteers using controlled flowrate and volume exposure cycles. Two main comparisons were made by measuring the systemic PK response: I. One label dose directly from the inhaler to the subject was compared to the same dose extracted from the pMDI into the PI system and then administered to the subject. II A small aerosol bolus at a penetration level in the central airways was compared to a small aerosol bolus at a penetration level in the peripheral lung.RESULTS AND CONCLUSIONS: When one inhaler dose was administered via the PI system, the absorbed dose, expressed as AUC24, was approximately twice as high and the CV was less than half, compared to direct inhalation from the same pMDI. Bolus breath hold targeting of drugs from the same aerosol mixture to the peripheral lung and the central airways showed a difference in their appearance in the systemic circulation. Normalized to the same deposited dose, SMX had a 57 % higher Cmax in the peripheral lung compared to the central airways. However, from 6 to 24 h after dosing the systemic concentrations of SMX from both regions were quite similar. FP had parallel concentrations curves with a 23 % higher AUC24 in the peripheral lung with no noticeable elevation around Cmax. The permeability of these two substances from similar sized aerosols was indeed higher in the thinner air/blood barriers of the peripheral lung compared to the central airways, but differences as measured on the venous side of the circulation were not dramatic. In conclusion, the PI system provided better control of actuation, aspiration, and dispensation of aerosols from the clinical inhaler and thereby delivered higher quality read outs of pharmacokinetic parameters such as tmax, Cmax, and AUC. Improved performance, using PI system, can likely also be employed for studying regional selectivity of other responses in the lungs, for use in drug development.

pharmacology & pharmacy
Pulmonary drug delivery and retention: A computational study to identify plausible parameters based on a coupled airway-mucus flow model

Aranyak Chakravarty,Mahesh V. Panchagnula,Alladi Mohan,Neelesh A. Patankar

DOI: https://doi.org/10.1371/journal.pcbi.1010143

2022-06-03

PLoS Computational Biology

Abstract:Pulmonary drug delivery systems rely on inhalation of drug-laden aerosols produced from aerosol generators such as inhalers, nebulizers etc. On deposition, the drug molecules diffuse in the mucus layer and are also subjected to mucociliary advection which transports the drugs away from the initial deposition site. The availability of the drug at a particular region of the lung is, thus, determined by a balance between these two phenomena. A mathematical analysis of drug deposition and retention in the lungs is developed through a coupled mathematical model of aerosol transport in air as well as drug molecule transport in the mucus layer. The mathematical model is solved computationally to identify suitable conditions for the transport of drug-laden aerosols to the deep lungs. This study identifies the conditions conducive for delivering drugs to the deep lungs which is crucial for achieving systemic drug delivery. The effect of different parameters on drug retention is also characterized for various regions of the lungs, which is important in determining the availability of the inhaled drugs at a target location. Our analysis confirms that drug delivery efficacy remains highest for aerosols in the size range of 1-5 μ m. Moreover, it is observed that amount of drugs deposited in the deep lung increases by a factor of 2 when the breathing time period is doubled, with respect to normal breathing, suggesting breath control as a means to increase the efficacy of drug delivery to the deep lung. A higher efficacy also reduces the drug load required to be inhaled to produce the same health effects and hence, can help in minimizing the side effects of a drug. Pulmonary drug delivery systems utilize the respiratory mechanism to directly deliver drugs to a target region of the lungs. The drug molecules deposit in the mucus lining, on reaching the target region, and are simultaneously transported away from the target region due to mucociliary transport and molecular diffusion. The availability of drugs at a target lung region and hence, efficacy of the drugs, therefore, determined by the delivery and retention of the drugs at the target region. The present study computationally solves the coupled transport equations to identify the conditions conducive for drug delivery and retention in the deep lungs. Drug delivery efficacy to the deep lung is observed to be highest for 1–5 μ m aerosols. Breathing time period is also observed to influence efficacy. The amount of drugs deposited in the deep lung is observed to increase by a factor of 2 when the breathing time period is doubled with respect to normal breathing period. Such insights gained from this analysis will potentially help in devising mechanisms for increasing drug availability in the deep lung which is essential in achieving systemic drug delivery.

biochemical research methods,mathematical & computational biology
Numerical and Experimental Analysis of Drug Inhalation in Realistic Human Upper Airway Model

Morsal Momeni Larimi,Arash Babamiri,Mohit Biglarian,Abas Ramiar,Reza Tabe,Kiao Inthavong,Ali Farnoud

DOI: https://doi.org/10.3390/ph16030406

2023-03-07

Abstract:The demand for a more efficient and targeted method for intranasal drug delivery has led to sophisticated device design, delivery methods, and aerosol properties. Due to the complex nasal geometry and measurement limitations, numerical modeling is an appropriate approach to simulate the airflow, aerosol dispersion, and deposition for the initial assessment of novel methodologies for better drug delivery. In this study, a CT-based, 3D-printed model of a realistic nasal airway was reconstructed, and airflow pressure, velocity, turbulent kinetic energy (TKE), and aerosol deposition patterns were simultaneously investigated. Different inhalation flowrates (5, 10, 15, 30, and 45 L/min) and aerosol sizes (1, 1.5, 2.5, 3, 6, 15, and 30 µm) were simulated using laminar and SST viscous models, with the results compared and verified by experimental data. The results revealed that from the vestibule to the nasopharynx, the pressure drop was negligible for flow rates of 5, 10, and 15 L/min, while for flow rates of 30 and 40 L/min, a considerable pressure drop was observed by approximately 14 and 10%, respectively. However, from the nasopharynx and trachea, this reduction was approximately 70%. The aerosol deposition fraction alongside the nasal cavities and upper airway showed a significant difference in pattern, dependent on particle size. More than 90% of the initiated particles were deposited in the anterior region, while just under 20% of the injected ultrafine particles were deposited in this area. The turbulent and laminar models showed slightly different values for the deposition fraction and efficiency of drug delivery for ultrafine particles (about 5%); however, the deposition pattern for ultrafine particles was very different.
Designing Aerosol Therapies Based on the Integrated Evaluation of In Vitro, In Vivo, and In Silico Data

Margaret Bourlon,Yu Feng,Lucila Garcia-Contreras

DOI: https://doi.org/10.3390/pharmaceutics15061695

IF: 6.525

2023-06-09

Pharmaceutics

Abstract:Despite the advantages of the pulmonary route of administration and inhalable dosage forms, other routes of administration and dosage forms are often considered first to treat lung diseases. This occurs, in part, due to the perceived limitations of inhaled therapies resulting from the improper design and interpretation of their in vitro and in vivo evaluation. The present study outlines the elements that should be considered in the design, performance, and interpretation of the results of the preclinical evaluation of novel inhaled therapies. These elements are illustrated using an optimized model poly(lactic-co-glycolic) acid (PLGA) microparticle (MP) formulation to optimize the site of MPs deposition. The different expressions of MP size were determined, and their aerosol performance in devices used for animal (Microsprayer® and Insufflator®) and human studies (nebulizer and DPIs) was assessed using inertial impaction. Radiolabeled MPs were delivered to the lungs of rats by spray instillation to determine their site of deposition using single-photon emission computed tomography (SPECT) imaging. Recommendations to optimize the in vitro determinations are given, as well as suggestions to evaluate and interpret in vivo data in the context of the anatomy and physiology of the animal model and the corresponding in vitro data. Recommendations for the proper selection of in vitro parameters to inform in silico modeling are also given, as well as their integration with in vivo data.
Identifying the optimal parameters for sprayed and inhaled drug particulates for intranasal targeting of SARS-CoV-2 infection sites

Yueying Lao,Diane Joseph-McCarthy,Arijit Chakravarty,Pallavi A. Balivada,Phoebe Ato,Nogaye K. Ka,Saikat Basu

DOI: https://doi.org/10.48550/arXiv.2010.16325

2020-10-30

Abstract:Efficacy for COVID-19 treatments can be enhanced significantly through targeting the nasopharynx, which has been shown to be the dominant preliminary infection site for SARS-CoV-2. Although intranasal drugs can be administered easily through drops or sprays, it is difficult to test whether current protocols will deliver the right amount of the drug to this location consistently. We are interested in developing an in silico prototyping tool to rapidly identify optimal parameters for intranasal delivery. In this study, we have applied computational fluid dynamics to simulate fluid flow through the nasal cavity and examined particle deposition for a drug formulation, mimicking different delivery methods. The nasal geometry models were derived using digitized and meshed computed tomography (CT) scans of human patients. Using the nasal geometries, we simulated two different airflows: a laminar model at 15 LPM (Liters/min) that simulated resting breathing rate and a Large Eddy Simulation (LES) model used to achieve a higher flow rate of 30 LPM. We were able to run particle tracking simulations for these two airflow schemes to test different drug properties such as particle size. The different injection methods used include surface injection which best replicates an inhaler-based release of particle droplets into the nostril and the cone injection method which best replicates a spray into the nostril. The results of the study suggest that the most optimal drug particle size for targeting the intranasal infection sites is around 6-14 microns.

Medical Physics
Recent Advancement in Inhaled Nano-drug Delivery for Pulmonary, Nasal, and Nose-to-brain Diseases

Qiuxia Fu,Yangjie Liu,Cao Peng,Tobias Achu Muluh,Umer Anayyat,Liu Liang

DOI: https://doi.org/10.2174/0115672018268047231207105652

2024-01-24

Current Drug Delivery

Abstract:Abstract: Pulmonary, nasal, and nose-to-brain diseases involve clinical approaches, such as bronchodilators, inhaled steroids, oxygen therapy, antibiotics, antihistamines, nasal steroids, decongestants, intranasal drug delivery, neurostimulation, and surgery to treat patients. However, systemic medicines have serious adverse effects, necessitating the development of inhaled formulations that allow precise drug delivery to the airways with minimum systemic drug exposure. Particle size, surface charge, biocompatibility, drug capacity, and mucoadhesive are unique chemical and physical features that must be considered for pulmonary and nasal delivery routes due to anatomical and permeability considerations. The traditional management of numerous chronic diseases has a variety of drawbacks. As a result, targeted medicine delivery systems that employ nanotechnology enhancer drug efficiency and optimize the overall outcome are created. The pulmonary route is one of the most essential targeted drug delivery systems because it allows the administering of drugs locally and systemically to the lungs, nasal cavity, and brain. Furthermore, the lungs' beneficial characteristics, such as their ability to inhibit first-pass metabolism and their thin epithelial layer, help treat several health complications. The potential to serve as noninvasive self-administration delivery sites of the lung and nasal routes is discussed in this script. New methods for treating respiratory and some systemic diseases with inhalation have been explored and highlight particular attention to using specialized nanocarriers for delivering various drugs via the nasal and pulmonary pathways. The design and development of inhaled nanomedicine for pulmonary, nasal, and respiratory medicine applications is a potential approach for clinical translation.

pharmacology & pharmacy
Patch Use and Patch Depletion By the Spider and Howling Monkeys of Santa Rosa National Park, Costa Rica

C. Chapman

DOI: https://doi.org/10.1163/156853988X00467

Abstract:Patch depletion is an assumption that underlies many behavioural ecological models, yet it has rarely been examined. The evidence presented here suggests that the spider and howling monkeys of Santa Rosa National Park, Costa Rica use food resources that occur in patches and generally deplete the patches they use. However, some types of patches (e.g. large fruiting trees for spider monkeys, and trees used as sources of leaves for howlers) are not depleted by the feeding activity of primates. An examination of which types of patches are depleted and the manner in which depletion likely occurs, allows an assessment of possible factors underlying the different types of social organizations in these species.
Pulsatile Bi-Directional Aerosol Flow Affects Aerosol Delivery to the Intranasal Olfactory Region: A Patient-Specific Computational Study

Ali Farnoud,Hesam Tofighian,Ingo Baumann,Andrew R Martin,Mohammad M Rashidi,Micheal P Menden,Otmar Schmid

DOI: https://doi.org/10.3389/fphar.2021.746420

2021-11-23

Abstract:The nasal olfactory region is a potential route for non-invasive delivery of drugs directly from the nasal epithelium to the brain, bypassing the often impermeable blood-brain barrier. However, efficient aerosol delivery to the olfactory region is challenging due to its location in the nose. Here we explore aerosol delivery with bi-directional pulsatile flow conditions for targeted drug delivery to the olfactory region using a computational fluid dynamics (CFD) model on the patient-specific nasal geometry. Aerosols with aerodynamic diameter of 1 µm, which is large enough for delivery of large enough drug doses and yet potentially small enough for non-inertial aerosol deposition due to, e.g., particle diffusion and flow oscillations, is inhaled for 1.98 s through one nostril and exhaled through the other one. The bi-directional aerosol delivery with steady flow rate of 4 L/min results in deposition efficiencies (DEs) of 50.9 and 0.48% in the nasal cavity and olfactory region, respectively. Pulsatile flow with average flow rate of 4 L/min (frequency: 45 Hz) reduces these values to 34.4 and 0.12%, respectively, and it mitigates the non-uniformity of right-left deposition in both the cavity (from 1.77- to 1.33-fold) and the olfactory region (from 624- to 53.2-fold). The average drug dose deposited in the nasal cavity and the olfactory epithelium region is very similar in the right nasal cavity independent of pulsation conditions (inhalation side). In contrast, the local aerosol dose in the olfactory region of the left side is at least 100-fold lower than that in the nasal cavity independent of pulsation condition. Hence, while pulsatile flow reduces the right-left (inhalation-exhalation) imbalance, it is not able to overcome it. However, the inhalation side (even with pulsation) allows for relatively high olfactory epithelium drug doses per area reaching the same level as in the total nasal cavity. Due to the relatively low drug deposition in olfactory region on the exhalation side, this allows either very efficient targeting of the inhalation side, or uniform drug delivery by performing bidirectional flow first from the one and then from the other side of the nose.
Coarse spray delivery to a localized region of the pulmonary airways for gene therapy

D C Cipolla,I Gonda,S Shak,I Kovesdi,R Crystal,T D Sweeney

DOI: https://doi.org/10.1089/10430340050016085

2000-01-20

Abstract:Targeting adenoviral vectors for cystic fibrosis gene therapy to the human airways with minimal exposure to alveoli would avoid adverse reactions and maximize response. At present, to deliver gene therapy vectors, large volumes of fluid are instilled or nebulized as aerosols. Either approach would likely cause alveolar exposure and increases the potential for side effects. We describe a coarse spray delivery device that precisely and reproducibly delivers the viral vector to the human airways to treat a small region of the airways for clinical trials. An endoscopic washing pipe (Olympus) that can be inserted into the channel of a bronchoscope was used. To minimize the escape of the therapeutic material downstream from the site of administration, we restricted the volume delivered to <150 microl (to prevent bulk flow), and used large droplets. Their high velocity further enhanced the probability of impaction in the vicinity of the nozzle. A pneumatic dosing system (Kahnetics) was used to reproducibly deliver the spray. The droplet size distribution was determined by laser diffraction and confirmed by cascade impaction: 190-microm volume median diameter with 1% mass <10 microm. The localization of the spray was studied in hollow cast models of human airways. 99mTc-sulfur colloid was used as a radiolabeled marker for these studies. Localization of the deposited spray was determined by scintigraphy and by measuring the radioactivity exiting the terminal airways. In the lung casts the spray was localized to one or two generations over an approximately 2-cm2 area. We conclude that delivery of large droplet sprays limits exposure to a few generations and may be useful in topical gene delivery clinical trials.
Inhaled drug delivery: Past, present, and future

Ludan Yue,Xueyang Zhang,Chenchen Zhao,Rongchang Chen,Xiaoyuan Chen,Lang Rao

DOI: https://doi.org/10.1016/j.nantod.2023.101942

IF: 17.4

2023-08-03

Nano Today

Abstract:Inhaled drug delivery has been an emerging route for the treatment of lung diseases with clear advantages over oral and intravenous routes . However, the delivery efficacy is affected by multiple physiologic barriers including mechanical clearance, mucociliary clearance, macrophage phagocytosis and exhalation lymphatic transport in the respiratory tract. As such, research emphasis has been placed on the development of optimized carriers that could overcome these physiologic barriers via nebulization . In this review, we provided an overview of inhaled drug delivery methods to highlight non-invasive strategies for the treatment of lung diseases. The potential mechanisms of typical lung diseases and the history and development of pulmonary drug delivery methods are reviewed. Strategies to overcome the challenges of inhaled drug delivery methods are further discussed to highlight the advances made so far. Recent progress made on inhaled drug delivery methods based on various carriers are highlighted for the prospective development of pulmonary drug delivery nanoplatforms. We aim to give a systemic overview of inhaled drug delivery methods to promote the development of aerosolized nanomedicines while enabling functional designs for clinical applications, allowing precise and effective therapies against lung diseases.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Traditional pain management methods gain popularity.

J. Leak

Abstract:
Numerical study on the deposition distribution and mechanism of inhaled drug particles in various regions of the realistic inhaler-airway model

Lixing Zhang,Zhenbo Tong,Ya Zhang,Aibing Yu

DOI: https://doi.org/10.1016/j.powtec.2024.120402

IF: 5.64

2024-11-03

Powder Technology

Abstract:Inhaled drug delivery is widely used in the treatment of respiratory diseases. Understanding the deposition mechanisms of dry powder inhalers (DPIs) in different regions of the airway is crucial for inhaler development and prediction of the deposition distribution of drug particles. And the insertion of the inhaler will significantly alter the pattern of airflow in the airway. The main objective of this study is to systematically investigate the distribution and mechanism of aerosol particle deposition in various regions of the inhaler-airway model. Computational fluid dynamics (CFD) was used to simulate the effect of inhalation flow rate on the deposition of drug particles in various regions of the airway. The discrete phase model (DPM) was adopted to track the deposition trajectories of drug particles. Three different inhalation flow rates together with six particle sizes and five particle densities were analyzed. The results indicated that the overall deposition fraction of drug particles gradually increased with particle size and density. The pattern of depositional distribution in other local areas is quite different from the overall pattern except in the oral. The deposition fraction in the pharynx was much larger than in the other local regions, the deposition fractions in the larynx, trachea, carina and bronchi were less than 5 %. The increase in density increases the deposition fraction of particles in various regions throughout the respiratory tract when the inhalation flow rate is 30 L/min. Most of the particles in the oral are deposited on the tongue, and the particles in the bronchus are more distributed in the main trunk, while deeper in the bronchus, particles are also deposited in the bifurcation region. The subject's inhalation posture also affects the local distribution of the airflow. The findings of present study can help to guide the optimization and in vitro-in vivo correlation of DPIs.

engineering, chemical
Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications

N. R. Labiris,M. B. Dolovich

DOI: https://doi.org/10.1046/j.1365-2125.2003.01892.x

2003-08-20

British Journal of Clinical Pharmacology

Abstract:As the end organ for the treatment of local diseases or as the route of administration for systemic therapies, the lung is a very attractive target for drug delivery. It provides direct access to disease in the treatment of respiratory diseases, while providing an enormous surface area and a relatively low enzymatic, controlled environment for systemic absorption of medications. As a major port of entry, the lung has evolved to prevent the invasion of unwanted airborne particles from entering into the body. Airway geometry, humidity, mucociliary clearance and alveolar macrophages play a vital role in maintaining the sterility of the lung and consequently are barriers to the therapeutic effectiveness of inhaled medications. In addition, a drug's efficacy may be affected by where in the respiratory tract it is deposited, its delivered dose and the disease it may be trying to treat.

pharmacology & pharmacy
Micron particle deposition in a tracheobronchial airway model under different breathing conditions

Kiao Inthavong,Lok-Tin Choi,Jiyuan Tu,Songlin Ding,Francis Thien

DOI: https://doi.org/10.1016/j.medengphy.2010.08.012

2010-12-01

Abstract:Effective management of asthma is dependent on achieving adequate delivery of the drugs into the lung. Inhalers come in the form of dry powder inhalers (DPIs) and metered dose inhalers (pMDIs) with the former requiring a deep fast breath for activation while there are no restrictions on inhalation rates for the latter. This study investigates two aerosol medication delivery methods (i) an idealised case for drug particle delivery under a normal breathing cycle (inhalation-exhalation) and (ii) for an increased effort during the inhalation with a breath hold. A computational model of a human tracheobronchial airway was reconstructed from computerised tomography (CT) scans. The model's geometry and lobar flow distribution were compared with experimental and empirical models to verify the current model. Velocity contours and secondary flow vectors showed vortex formation downstream of the bifurcations which enhanced particle deposition. The velocity contour profiles served as a predictive tool for the final deposition patterns. Different spherical aerosol particle sizes (3-10μm, 1.55g/cm(3)) were introduced into the airway for comparison over a range of Stokes number. It was found that a deep inhalation with a breath hold of 2s did not necessarily increase later deposition up to the sixth branch generation, but rather there was an increase in the deposition in the first few airway generations was found. In addition the breath hold allows deposition by sedimentation which assists in locally targeted deposition. Visualisation of particle deposition showed local "hot-spots" where particle deposition was concentrated in the lung airway.

engineering, biomedical
In silico high-resolution whole lung model to predict the locally delivered dose of inhaled drugs

Maximilian J. Grill,Jonas Biehler,Karl-Robert Wichmann,David Rudlstorfer,Maximilian Rixner,Marie Brei,Jakob Richter,Joshua Bügel,Nina Pischke,Wolfgang A. Wall,Kei W. Müller

2023-07-11

Abstract:The big crux with drug delivery to human lungs is that the delivered dose at the local site of action is unpredictable and very difficult to measure, even a posteriori. It is highly subject-specific as it depends on lung morphology, disease, breathing, and aerosol characteristics. Given these challenges, computational approaches have shown potential, but have so far failed due to fundamental methodical limitations. We present and validate a novel in silico model that enables the subject-specific prediction of local aerosol deposition throughout the entire lung. Its unprecedented spatiotemporal resolution allows to track each aerosol particle anytime during the breathing cycle, anywhere in the complete system of conducting airways and the alveolar region. Predictions are shown to be in excellent agreement with in vivo SPECT/CT data for a healthy human cohort. We further showcase the model's capabilities to represent strong heterogeneities in diseased lungs by studying an IPF patient. Finally, high computational efficiency and automated model generation and calibration ensure readiness to be applied at scale. We envision our method not only to improve inhalation therapies by informing and accelerating all stages of (pre-)clinical drug and device development, but also as a more-than-equivalent alternative to nuclear imaging of the lungs.

Medical Physics,Computational Engineering, Finance, and Science
Modelling Drug Delivery to the Small Airways: Optimization Using Response Surface Methodology

Hyunhong J. Min,Stephen J. Payne,Eleanor P. Stride

DOI: https://doi.org/10.1007/s11095-024-03706-1

IF: 4.58

2024-05-18

Pharmaceutical Research

Abstract:The aim of this in silico study was to investigate the effect of particle size, flow rate, and tidal volume on drug targeting to small airways in patients with mild COPD.

pharmacology & pharmacy,chemistry, multidisciplinary
The Liebmann effect in binocular perception; preliminary studies.

M. H. Orzack,T. Schlaegel

DOI: https://doi.org/10.1016/0002-9394(55)90012-X

1955-02-01

Abstract:
Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence

Omar S Usmani,Nicolas Roche,Martin Jenkins,Neda Stjepanovic,Peter Mack,Wilfried De Backer

DOI: https://doi.org/10.2147/COPD.S274846

2021-01-18

Abstract:Metered dose inhalers (MDIs) are one of the most common device types for delivering inhaled therapies. However, there are several technical challenges in development and drug delivery of these medications. In particular, suspension-based MDIs are susceptible to suspension heterogeneity, in vitro drug-drug interactions, and patient handling errors, which may all affect drug delivery. To overcome these challenges, new formulation approaches are required. The AerosphereTM inhaler, formulated using co-suspension delivery technology, combines drug crystals with porous phospholipid particles to create stable, homogenous suspensions that dissolve once they reach the airways. Two combination therapies using this technology have been developed for the treatment of COPD: glycopyrrolate/formoterol fumarate (GFF MDI; dual combination) and budesonide/glycopyrrolate/formoterol fumarate (BGF MDI; triple combination). Here, we review the evidence with a focus on studies assessing dose delivery, lung deposition, and effects on airway geometry. In vitro assessments have demonstrated that the Aerosphere inhaler provides consistent dose delivery, even in the presence of simulated patient handling errors. Combination therapies delivered with this technology also show a consistent fine particle fraction (FPF) and an optimal particle size distribution for delivery to the central and peripheral airways even when multiple drugs are delivered via the same inhaler. Studies using gamma scintigraphy and functional respiratory imaging have demonstrated that GFF MDI is effectively deposited in the central and peripheral airways, and provides clinically meaningful benefits on airway volume and resistance throughout the lung. Overall, studies suggest that the Aerosphere inhaler, formulated using co-suspension delivery technology, may offer advantages over traditional formulations, including consistent delivery of multiple components across patient handling conditions, optimal particle size and FPF, and effective delivery to the central and peripheral airways. Future studies may provide additional evidence to further characterize the clinical benefits of these technical improvements in MDI drug delivery.

Mixed colloids and acute kidney injury: a case of selection bias?

An In Silico Investigation of a Lobe-Specific Targeted Pulmonary Drug Delivery Method

Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System

Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale® system: A first evaluation in humans

Pulmonary drug delivery and retention: A computational study to identify plausible parameters based on a coupled airway-mucus flow model

Numerical and Experimental Analysis of Drug Inhalation in Realistic Human Upper Airway Model

Designing Aerosol Therapies Based on the Integrated Evaluation of In Vitro, In Vivo, and In Silico Data

Identifying the optimal parameters for sprayed and inhaled drug particulates for intranasal targeting of SARS-CoV-2 infection sites

Recent Advancement in Inhaled Nano-drug Delivery for Pulmonary, Nasal, and Nose-to-brain Diseases

Patch Use and Patch Depletion By the Spider and Howling Monkeys of Santa Rosa National Park, Costa Rica

Pulsatile Bi-Directional Aerosol Flow Affects Aerosol Delivery to the Intranasal Olfactory Region: A Patient-Specific Computational Study

Coarse spray delivery to a localized region of the pulmonary airways for gene therapy

Inhaled drug delivery: Past, present, and future

Traditional pain management methods gain popularity.

Numerical study on the deposition distribution and mechanism of inhaled drug particles in various regions of the realistic inhaler-airway model

Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications

Micron particle deposition in a tracheobronchial airway model under different breathing conditions

In silico high-resolution whole lung model to predict the locally delivered dose of inhaled drugs

Modelling Drug Delivery to the Small Airways: Optimization Using Response Surface Methodology

The Liebmann effect in binocular perception; preliminary studies.

Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence